AP201609368A0 - Heteroaryls and uses thereof - Google Patents

Heteroaryls and uses thereof

Info

Publication number
AP201609368A0
AP201609368A0 AP201609368A AP201609368A AP201609368A0 AP 201609368 A0 AP201609368 A0 AP 201609368A0 AP 201609368 A AP201609368 A AP 201609368A AP 201609368 A AP201609368 A AP 201609368A AP 201609368 A0 AP201609368 A0 AP 201609368A0
Authority
AP
ARIPO
Prior art keywords
heteroaryls
uses
Prior art date
Application number
AP201609368A
Inventor
Indu T Bharathan
Chris Blackburn
Jeffrey P Ciavarri
Jouhara Chouitar
Courtney A Cullis
Amore Natalie D
Paul E Fleming
Kenneth M Gigstad
Krista E Gipson
Mario Girard
Yongbo Hu
Janice Lee
Gang Li
Mansoureh Rezaei
Michael D Sintchak
Francois Soucy
Stephen G Stroud
Tricia J Vos
Tzu-Tshin Wong
He Xu
Tianlin Xu
Yingchun Ye
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US201461927055P priority Critical
Priority to US201462054742P priority
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Priority to PCT/US2015/011191 priority patent/WO2015108861A1/en
Publication of AP201609368A0 publication Critical patent/AP201609368A0/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53543363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP201609368(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
AP201609368A 2014-01-14 2015-01-13 Heteroaryls and uses thereof AP201609368A0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US201461927055P true 2014-01-14 2014-01-14
US201462054742P true 2014-09-24 2014-09-24
PCT/US2015/011191 WO2015108861A1 (en) 2014-01-14 2015-01-13 Heteroaryls and uses thereof

Publications (1)

Publication Number Publication Date
AP201609368A0 true AP201609368A0 (en) 2016-08-31

Family

ID=53543363

Family Applications (1)

Application Number Title Priority Date Filing Date
AP201609368A AP201609368A0 (en) 2014-01-14 2015-01-13 Heteroaryls and uses thereof

Country Status (23)

Country Link
US (3) US9802960B2 (en)
EP (1) EP3094325A4 (en)
JP (1) JP6609258B2 (en)
KR (1) KR20160122736A (en)
CN (1) CN105916503A (en)
AP (1) AP201609368A0 (en)
AU (1) AU2015206652A1 (en)
BR (1) BR112016016289A2 (en)
CA (1) CA2935867A1 (en)
CL (1) CL2016001805A1 (en)
CR (1) CR20160363A (en)
DO (1) DOP2016000173A (en)
EA (1) EA032458B1 (en)
GE (1) GEP20196983B (en)
IL (1) IL246755D0 (en)
MX (1) MX2016009135A (en)
PE (1) PE20161313A1 (en)
PH (1) PH12016501388A1 (en)
SG (1) SG11201604820XA (en)
TN (1) TN2016000270A1 (en)
TW (1) TWI662024B (en)
UY (1) UY35951A (en)
WO (1) WO2015108861A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104230922B (en) 2013-06-19 2016-12-28 中国科学院上海药物研究所 One class five-ring heterocycles pyridine compounds and their and its production and use
US10202373B2 (en) 2014-01-14 2019-02-12 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2015108861A1 (en) * 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
JP2018532737A (en) * 2015-10-21 2018-11-08 大塚製薬株式会社 Benzolactam compounds
AU2017219846A1 (en) 2016-02-19 2018-10-04 Sprint Bioscience Ab 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes
AU2017219847A1 (en) 2016-02-19 2018-10-04 Sprint Bioscience Ab 6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes
WO2018144791A1 (en) * 2017-02-03 2018-08-09 Millennium Pharmaceuticals, Inc. Combination of vps34 inhibitors and mtor inhibitors
GB201706327D0 (en) * 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
WO2019038384A1 (en) 2017-08-23 2019-02-28 Sprint Bioscience Ab Azaindolylpyridone and diazaindolylpyridone compounds
WO2019038389A1 (en) 2017-08-23 2019-02-28 Sprint Bioscience Ab Pyridinamine-pyridone and pyrimidinamine-pyridone compounds
TW201912630A (en) 2017-08-23 2019-04-01 瑞典商斯普林特生物科技公司 Pyridyl pyridone compound
TW201912161A (en) 2017-08-23 2019-04-01 瑞典商斯普林特生物科技公司 Morpholino pyridone compound
WO2019052932A1 (en) 2017-09-18 2019-03-21 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT454378T (en) 2002-11-01 2010-01-15 Vertex Pharma Compounds suited as inhibitors of jak and other protein kinases
FR2850652B1 (en) 2003-01-31 2008-05-30 Aventis Pharma Sa Novel cyclic urea derivatives, their preparation and their pharmaceutical use as inhibitors of kinases
SE0402735D0 (en) 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
EP1814856A1 (en) 2004-11-12 2007-08-08 Galapagos N.V. Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
EP1831168B1 (en) 2004-12-16 2014-07-02 Vertex Pharmaceuticals Inc. Pyrid-2-ones useful as inhibitors of tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases.
CN101111479A (en) * 2004-12-16 2008-01-23 沃泰克斯药物股份有限公司 Pyridones used as inhibitors of kinases
US7601716B2 (en) 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
WO2007135398A1 (en) 2006-05-22 2007-11-29 Astrazeneca Ab Indole derivatives
US20080280891A1 (en) 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
WO2008008059A1 (en) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof
MX2009002171A (en) 2006-08-30 2009-05-28 Cellzome Ltd Triazole derivatives as kinase inhibitors.
UA96964C2 (en) 2006-12-04 2011-12-26 Астразенека Аб Antibacterial polycyclic urea compounds
WO2008079933A2 (en) 2006-12-22 2008-07-03 Novartis Ag Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections
UY31137A1 (en) 2007-06-14 2009-01-05 Smithkline Beecham Corp Quinazoline derivatives as inhibitors of PI3 kinase
EP2173722B1 (en) 2007-07-26 2012-08-29 Novartis AG Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions
US7928140B2 (en) 2007-08-02 2011-04-19 Amgen Inc. Benzothiazole PI3 kinase modulators for cancer treatment
EP2217590A4 (en) 2007-09-17 2011-12-14 Glaxosmithkline Llc Pyridopyrimidine derivatives as pi3 kinase inhibitors
WO2009055418A1 (en) 2007-10-22 2009-04-30 Smithkline Beecham Corporation Pyridosulfonamide derivatives as pi3 kinase inhibitors
JP5520831B2 (en) 2007-12-19 2014-06-11 アムジエン・インコーポレーテツド Inhibitors of PI3 kinase
US8343966B2 (en) 2008-01-11 2013-01-01 Novartis Ag Organic compounds
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
US8309577B2 (en) 2008-04-23 2012-11-13 Bristol-Myers Squibb Company Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands
AU2009260447B2 (en) 2008-05-30 2012-03-29 Amgen Inc. Inhibitors of PI3 kinase
EP2280946B1 (en) 2008-06-05 2016-02-10 Glaxo Group Limited 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases
US20110178070A1 (en) 2008-06-24 2011-07-21 Takeda Pharmaceutical Company Limited PI3K/mTOR INHIBITORS
WO2010007100A1 (en) 2008-07-15 2010-01-21 Cellzome Ltd 7-substituted amino triazoles as pi3k inhibitors
MX2011001349A (en) 2008-08-04 2011-08-17 Chidi Inc Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof.
CA2743242A1 (en) 2008-11-11 2010-05-20 Eli Lilly And Company P70 s6 kinase inhibitor and mtor inhibitor combination therapy
WO2010057877A1 (en) 2008-11-18 2010-05-27 Cellzome Limited 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors
US8071605B2 (en) 2008-12-12 2011-12-06 Astrazeneca Ab Piperidine compounds for use in the treatment of bacterial infections
JP2012527474A (en) 2009-05-22 2012-11-08 エクセリクシス, インク. Benzoxazepine-based PI3K / MT0R inhibitors for proliferative diseases
CN102471339A (en) 2009-07-15 2012-05-23 雅培制药有限公司 Pyrrolopyridine inhibitors of kinases
CA2771563A1 (en) * 2009-09-04 2011-03-10 Novartis Ag Bipyridines useful for the treatment of proliferative diseases
BR112012018954A2 (en) 2010-02-05 2016-04-12 Merck Patent Gmbh hetaryl- [1,8] naphthyridine derivatives
KR20130131293A (en) * 2010-07-05 2013-12-03 메르크 파텐트 게엠베하 Bipyridyl derivatives useful for the treatment of kinase - induced diseases
WO2012009227A1 (en) 2010-07-16 2012-01-19 N30 Pharmaceuticals, Llc Novel dihydropyridin-2(1h)-one compounds as s-nitrosoglutathione reductase inhibitors and neurokinin-3 receptor antagonists
EP2598481B1 (en) 2010-07-26 2016-08-31 Bristol-Myers Squibb Company Sulfonamide compounds useful as cyp17 inhibitors
WO2012021615A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US8478700B2 (en) 2010-08-11 2013-07-02 Brightedge Technologies, Inc. Opportunity identification and forecasting for search engine optimization
PE20131304A1 (en) 2010-08-11 2013-11-14 Millennium Pharm Inc Heterocycles and their uses
WO2012037108A1 (en) 2010-09-13 2012-03-22 Glaxosmithkline Llc Aminoquinoline derivatives as antiviral agents
EA201390717A1 (en) 2010-11-17 2013-10-30 Новартис Аг 3- (aminoaril) pyridine connections
WO2012066065A1 (en) 2010-11-17 2012-05-24 Novartis Ag Phenyl-heteroaryl amine compounds and their uses
US8685993B2 (en) * 2010-12-21 2014-04-01 Novartis Ag Bi-heteroaryl compounds as Vps34 inhibitors
WO2012085244A1 (en) 2010-12-23 2012-06-28 Sanofi Pyrimidinone derivatives, preparation thereof and pharmaceutical use thereof
WO2012101064A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
WO2012101066A1 (en) 2011-01-28 2012-08-02 Novartis Ag Pyridine biaryl amine compounds and their uses
JP2014506878A (en) 2011-01-28 2014-03-20 ノバルティス アーゲー Substituted bi-heteroaryl compounds as CDK9 inhibitors and their use
DE102011077104A1 (en) 2011-06-07 2012-12-13 Siemens Aktiengesellschaft Process for the recovery of metal-containing recyclables from a metal-containing valuable substances containing suspension-like mass flow
KR101502500B1 (en) 2011-07-01 2015-03-16 주식회사 엘지화학 Nonaqueous electrolyte and lithium secondary battery using the same
CN103958500B (en) * 2011-10-10 2016-04-27 奥赖恩公司 Kinases inhibitor
TW201332988A (en) 2011-12-23 2013-08-16 Millennium Pharm Inc Heteroaryls and uses thereof
CN104334527B (en) 2012-02-22 2017-05-24 桑福德-伯纳姆医学研究院 Sulfonamide compounds and uses as tnap inhibitors
WO2013152063A1 (en) * 2012-04-05 2013-10-10 Boehringer Ingelheim International Gmbh Naphthyridinone derivatives as inhibitors of cytomegalovirus dna polymerase
FR2992314B1 (en) 2012-06-22 2015-10-16 Sanofi Sa Novel 2,3-dihydro-1h-imidazo {1,2-a} pyrimidin-5-one and 1,2,3,4-tetrahydro-pyrimido {1,2-a} pyrimidin-6-one derivatives comprising a substituted morpholine, their preparation and their pharmaceutical use
EP2903613B1 (en) * 2012-10-08 2017-11-22 Merck Sharp & Dohme Corp. Pyrazole derivatives useful as inhibitors of irak4 activity
WO2014083327A1 (en) 2012-11-27 2014-06-05 Md Pharma Ab Adenine derivatives suitable for the treatment of (inter alia) muscular dystrophy
GB201223265D0 (en) 2012-12-21 2013-02-06 Selvita Sa Novel benzimidazole derivatives as kinase inhibitors
WO2014109414A1 (en) * 2013-01-11 2014-07-17 富士フイルム株式会社 Nitrogen-containing heterocylic compound or salt thereof
JP2016516710A (en) * 2013-03-13 2016-06-09 アッヴィ・インコーポレイテッド Pyridine CDK9 kinase inhibitor
US9242969B2 (en) * 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
WO2015108861A1 (en) 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US10202373B2 (en) 2014-01-14 2019-02-12 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof

Also Published As

Publication number Publication date
UY35951A (en) 2015-07-31
US20150225422A1 (en) 2015-08-13
PE20161313A1 (en) 2016-12-17
EA032458B1 (en) 2019-05-31
US9751854B2 (en) 2017-09-05
EP3094325A4 (en) 2017-08-09
JP2017503813A (en) 2017-02-02
CA2935867A1 (en) 2015-07-23
DOP2016000173A (en) 2016-12-15
TW201613865A (en) 2016-04-16
TWI662024B (en) 2019-06-11
US20170073326A1 (en) 2017-03-16
WO2015108861A1 (en) 2015-07-23
KR20160122736A (en) 2016-10-24
US9802960B2 (en) 2017-10-31
MX2016009135A (en) 2016-10-05
EP3094325A1 (en) 2016-11-23
US20180118762A1 (en) 2018-05-03
GEP20196983B (en) 2019-06-25
PH12016501388A1 (en) 2016-08-15
SG11201604820XA (en) 2016-07-28
TN2016000270A1 (en) 2017-10-06
CL2016001805A1 (en) 2017-07-07
JP6609258B2 (en) 2019-11-20
EA201691421A1 (en) 2017-05-31
IL246755D0 (en) 2016-08-31
CN105916503A (en) 2016-08-31
AU2015206652A1 (en) 2016-08-04
CR20160363A (en) 2016-10-12
BR112016016289A2 (en) 2018-05-08

Similar Documents

Publication Publication Date Title
GB201413018D0 (en) Beyond 1A
HK1217861A1 (en) Wifi-coordinated laa-lte
IL249186D0 (en) Anti-cd20 glycoantibodies and uses thereof
IL249188D0 (en) Anti-her2 glycoantibodies and uses thereof
SG11201608340UA (en) Cyclopropanamine compound and use thereof
IL249184D0 (en) Anti-tnf-alpha glycoantibodies and uses thereof
AU362912S (en) Wristband
IL255577D0 (en) Tigit-binding agents and uses thereof
GB201411197D0 (en) Composition and use thereof
IL253433D0 (en) Tnfrsf-binding agents and uses thereof
HK1225383A1 (en) Diazepane derivatives and uses thereof
EP3161135A4 (en) Plant-endophyte combinations and uses therefor
EP3157552A4 (en) Syntac polypeptides and uses thereof
BR112016016289A2 (en) heteroari and uses thereof
SG11201702603RA (en) Organosilica materials and uses thereof
IL251248D0 (en) Anti-interleukin-33 antibodies and uses thereof
GB201419094D0 (en) Anti-TIM-3-antibodies
GB201404893D0 (en) Selfie - Stick
AU359704S (en) Case
GB201502152D0 (en) Novel use
SG11201608943VA (en) Substituted 4-phenylpiperidines, their preparaiton and use
IL247847D0 (en) Ror-gamma modulators and uses thereof
RS59077B1 (en) Anti-egfrviii antibodies and uses thereof
AU361515S (en) Dishrack
SG11201703579UA (en) Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines